prikaz prve stranice dokumenta Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events
  Preuzmi
PDF 1.13 MB
Znanstveni rad - Izvorni znanstveni rad
Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events
The American Journal of Emergency Medicine, 70 (2023); 41-45. https://doi.org/10.1016/j.ajem.2023.05.007
Lucijanić, Marko; Bistrović, Petra; Jordan, Ana; Mihaljević, Iva; Bukvić, Stela; Kovačević, Stjepan; Ranilović, Darjan; Sakota, Sara; Vlasac Glasnović, Josipa; Delić-Brkljačić, Diana

Citirajte ovaj rad

Lucijanić, M., Bistrović, P., Jordan, A., Mihaljević, I., Bukvić, S., Kovačević, S. ... Delić Brkljačić, D. (2023). Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events. The American Journal of Emergency Medicine, 70., 41-45. doi: 10.1016/j.ajem.2023.05.007

Lucijanić, Marko, et al. "Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events." The American Journal of Emergency Medicine, vol. 70, 2023, str. 41-45. https://doi.org/10.1016/j.ajem.2023.05.007

Lucijanić, Marko, Petra Bistrović, Ana Jordan, Iva Mihaljević, Stela Bukvić, Stjepan Kovačević, Darjan Ranilović, Sara Sakota, Josipa Vlasac Glasnović i Diana Delić Brkljačić. "Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events." The American Journal of Emergency Medicine 70 (2023): 41-45. https://doi.org/10.1016/j.ajem.2023.05.007

Lucijanić, M., et al. (2023) 'Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events', The American Journal of Emergency Medicine, 70, str. 41-45. doi: 10.1016/j.ajem.2023.05.007

Lucijanić M, Bistrović P, Jordan A, Mihaljević I, Bukvić S, Kovačević S, i sur.. Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events. The American Journal of Emergency Medicine [Internet]. 08.2023. [pristupljeno 29.11.2024.];70:41-45. doi: 10.1016/j.ajem.2023.05.007

M. Lucijanić, et al., "Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events", The American Journal of Emergency Medicine, vol. 70, str. 41-45, Kolovoz 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:923043. [Citirano: 29.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:923043
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events
AutorMarko Lucijanić
AutorPetra Bistrović
AutorAna Jordan
AutorIva Mihaljević
AutorStela Bukvić
AutorStjepan Kovačević
AutorDarjan Ranilović
AutorSara Sakota
AutorJosipa Vlasac Glasnović
AutorDiana Delić-Brkljačić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Introduction: Venous thromboembolism (VTE) and arterial thrombotic (AT) events are a striking feature of severe COVID-19, however, relationship of remdesivir use and the risk of thrombotic events is unknown and has not been investigated before. Methods: We retrospectively analyzed a cohort of 876 consecutive hospitalized severe and critical COVID-19 patients who were treated with remdesivir and compared them to 876 case-matched control patients. All patients were treated in our tertiary-level institution in period from 10/2020 to 6/2021. VTE and AT were diagnosed by objective imaging and laboratory methods. Results: After exclusion of 71 VTE and 37 AT events present at the time of hospital admission, there were a total of 70 VTE (35 in the remdesivir and 35 in the control group) and 38 AT events occurring during hospitalization (13 in the remdesivir and 25 in the control group). There was a similar cumulative post-admission VTE incidence among both remdesivir and matched control patients (P = 0.287). Significantly lower cumulative post-admission AT incidence was observed among patients treated with remdesivir than among matched control patients (1.7% vs 3.3%, HR = 0.51, P = 0.035). Tendency for lower AT rates was evident in subgroups of patients stratified according to the type of AT, as well as according to the intensity of required oxygen supplementation at the time of remdesivir use. Conclusion: Remdesivir use in severe and critical COVID-19 patients might be associated with lower occurrence of AT during hospitalization, whereas similar rates of VTE events were observed among both patients treated with remdesivir and control patients.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaThe American Journal of Emergency Medicine
Brojčani podacivol. 70, str. 41-45
p-ISSN0735-6757
DOIhttps://doi.org/10.1016/j.ajem.2023.05.007
URN:NBNurn:nbn:hr:105:923043
Datum objave publikacije2023-08
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S0735675723002516
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2023-10-06 08:16:54